Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

DURECT (NASDAQ:DRRX – Get Free Report) is expected to post its quarterly earnings results before the market opens on ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

Inventiva (NASDAQ:IVA – Get Free Report) is projected to issue its quarterly earnings data before the market opens on ...

The liver is essential for digestion, metabolism, detoxification, and fluid regulation. While alcohol abuse is a known cause ...

In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...

Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. It is the progressive ...

For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as ...

† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...